2019
Proteomics AGM Presentation
28/11/2019Outcome of General Annual Meeting
26/11/2019Cutting-edge Protein Biomarker Analysis Facility for Western Australia
15/11/2019Proteomics International raises $3m in heavily oversubscribed Placement
12/11/2019CE Mark for predictive test for diabetic kidney disease
31/10/2019Appendix 4C – September 2019 Quarterly Report
29/10/2019Proteomics receives $1.1 million in R&D tax incentive
21/10/2019Notice of Annual General Meeting/Proxy Form
21/10/2019PIQ market update
17/09/2019PromarkerD IVD successfully developed and validated
13/09/2019PromarkerD launched in Spain
12/09/2019PromarkerD test ready for launch in Europe
10/09/2019PromarkerD latest results published in peer reviewed journal
30/08/2019Annual Report to shareholders
30/08/2019Appendix 4E – Preliminary Final Report
30/08/2019Corporate Governance Statement and Appendix 4G
30/07/2019Appendix 4C – June 2019 Quarterly Report
29/07/2019PromarkerD secures TGA software approval & Indonesian patent
26/07/2019Proteomics secures contracts for pharmacokinetic analysis
13/06/2019PIQ investor presentation – 121 Tech Investment Hong Kong
07/06/2019PromarkerD to feature at world’s largest diabetes conference
03/06/2019Proteomics to showcase PromarkerD at BIO Convention
23/05/2019Exercise of Options – Secondary Trading Notice & Appendix 3B
24/04/2019Appendix 4C – March 2019 Quarterly Report
27/02/2019Appendix 4D and Interim Financial Report
22/02/2019US patent for identifying drugs for abnormal kidney function
30/01/2019Appendix 4C – December 2018 Quarterly Report
24/01/2019PromarkerD US market update
15/01/2019Exercise of Options – Secondary Trading Notice & Appendix 3B
